Amgen: Blockbusters, Emerging Therapies, And Investment Potential

Company Overview - Amgen Inc is a biotechnology company with a strong track record in developing and commercializing products in four main therapeutic areas: general medicine, rare disease, oncology, and inflammation/immunology [1] - The company reported a 24% revenue growth in its Q3 2024 financial report [1] Analyst Background - The analyst has a background in life sciences with a PhD in Bioengineering and over 20 years of experience in research and development of novel Cell & Gene Therapies (CGT) [1] - The analyst focuses on analyzing biotechnology, pharmaceutical, Medtech, and healthcare stocks, leveraging their expertise to assess the potential of novel treatments and their impact on shareholder returns [1] Disclosure and Position - The analyst holds a beneficial long position in Amgen Inc through stock ownership, options, or other derivatives [2] - The analyst wrote the article independently and is not receiving compensation for it other than from Seeking Alpha [2]